During a meeting at the St. Petersburg International Economic Forum (SPIEF), Igor Kobzev, the head of the Irkutsk region, and Vikram Punia, the president of Pharmasyntez group, discussed the implementation of a new investment project of a bronchodilator manufacturing facility in the region. This was reported in the press service of the regional government.
Bronchodilators are drugs that relieve the symptoms of bronchospasm and are used in the treatment of bronchial asthma and chronic obstructive pulmonary disease.
“It is planned to launch production of hormonal and non-hormonal drugs at two sites. The total cost of the project is 1 billion rubles. The production volume is going to be 136 million capsules for dry powder inhalers and 867,000 inhalation aerosols per year. The products are scheduled to enter circulation in the first quarter of 2024,” the report says.
The Government of the Irkutsk region and AO Pharmasyntez concluded a supplementary agreement to the previously signed document on socio-economic cooperation. It includes a list of social activities for 2022 to be carried out at the expense of AO Pharmasyntez for the socio-economic development of the region.
“Pharmasyntez has been a reliable partner of the Irkutsk region for a quarter of a century and is one of the largest taxpayers in the region. Russian manufacturers have all the conditions for the development of the drug market. The pharmaceutical industry of the Irkutsk region is growing rapidly. Since the beginning of the year, the production of medicines has increased by 48%,” Kobzev said.
